Technical Analysis for IMUC - ImmunoCellular Therapeutics, Ltd.

Grade Last Price % Change Price Change
grade F 0.039 -26.42% -0.01
IMUC closed down 26.42 percent on Thursday, October 25, 2018, on 2.46 times normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. The bears made the stock sink to a new 52-week low. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Down Down
See historical IMUC trend table...

Date Alert Name Type % Chg
Oct 25 New 52 Week Closing Low Bearish 0.00%
Oct 25 New Downtrend Bearish 0.00%
Oct 25 Gilligan's Island Buy Setup Bullish Swing Setup 0.00%
Oct 25 Narrow Range Bar Range Contraction 0.00%
Oct 25 NR7 Range Contraction 0.00%
Oct 25 New 52 Week Low Weakness 0.00%
Oct 25 Stochastic Reached Oversold Weakness 0.00%
Oct 25 Wide Bands Range Expansion 0.00%
Oct 25 Below Lower BB Weakness 0.00%
Oct 25 Down 3 Days in a Row Weakness 0.00%

Older signals for IMUC ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
ImmunoCellular Therapeutics, Ltd., a clinical-stage biotechnology company, engages in developing and commercializing immune-based therapies for the treatment of brain, ovarian, and other solid tumors. Its lead pipeline product is ICT-107, a therapeutic dendritic cell (DC) vaccine, which is in Phase IIb clinical trial for the treatment of glioblastoma multiforme (GBM) that is a common and lethal type of brain cancer. The company also develops other therapeutic DC vaccines, such as ICT-121 to treat recurrent GBM, as well as solid tumors, including ovarian, pancreatic, and breast cancers; ICT-140 that targets 7 tumor-associated antigens expressed on ovarian cancer cells; and ICT-109, a monoclonal antibody product candidate to detect pancreatic and lung cancer in plasma and serum. In addition, it has a differential immunization for antigen and antibody discovery (DIAAD) platform that utilizes immunological tolerization to accelerate the discovery of the molecular differences between diseased cells and their normal counterparts. The company is based in Woodland Hills, California.
Is IMUC a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 0.55
52 Week Low 0.0308
Average Volume 479,236
200-Day Moving Average 0.2506
50-Day Moving Average 0.2158
20-Day Moving Average 0.2007
10-Day Moving Average 0.1896
Average True Range 0.0268
ADX 27.38
+DI 10.7762
-DI 55.1614
Chandelier Exit (Long, 3 ATRs ) 0.1746
Chandelier Exit (Short, 3 ATRs ) 0.1112
Upper Bollinger Band 0.3052
Lower Bollinger Band 0.0962
Percent B (%b) -0.27
BandWidth 104.135526
MACD Line -0.0246
MACD Signal Line -0.0076
MACD Histogram -0.017
Fundamentals Value
Market Cap 618.09 Thousand
Num Shares 15.8 Million
EPS -6.01
Price-to-Earnings (P/E) Ratio -0.01
Price-to-Sales 0.00
Price-to-Book 0.00
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 0.05
Resistance 3 (R3) 0.05 0.05 0.05
Resistance 2 (R2) 0.05 0.04 0.05 0.05
Resistance 1 (R1) 0.04 0.04 0.04 0.04 0.05
Pivot Point 0.04 0.04 0.04 0.04 0.04
Support 1 (S1) 0.03 0.03 0.03 0.03 0.03
Support 2 (S2) 0.03 0.03 0.03 0.03
Support 3 (S3) 0.02 0.03 0.03
Support 4 (S4) 0.02